Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Variagenics/Hyseq proceeds, rival bid rejected:

This article was originally published in Clinica

Executive Summary

The shareholders of Cambridge, Massachusetts-based molecular diagnostics firm Variagenics and of Sunnyvale, California biopharma company Hyseq Pharmaceuticals have approved plans to merge. The deal is expected to close on January 31. The new group will be renamed Nuvelo and will begin trading on Nasdaq on February 3. A few days before the approval, Variagenics' board of directors urged shareholders to reject a rival bid from Acacia Research, a technology investment group that wanted to integrate Variagenics into its CombiMatrix life science biochip subsidiary. Variagenics' board favoured the biotherapeutic/diagnostic business model over a research tool focus.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060941

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel